Brief: Ipsen: Elafibranor Shows Favorable Safety Profile And Efficacy In PSC
24/04/2025 07:16
April 24 (Reuters) - Ipsen SA IPN.PA: ELAFIBRANOR SHOWS FAVORABLE SAFETY PROFILE AND EFFICACY IN PSC A SIGNIFICANT IMPROVEMENT IN PRURITUS WAS OBSERVED IN PATIENTS ON ELAFIBRANOR 120 MG VERSUS PLACEBO ELAFIBRANOR IMPROVES LIVER BIOCHEMICAL PARAMETERS IN PSC PATIENTS PHASE II ELMWOOD TRIAL SHOWS POSITIVE SAFETY AND EFFICACY FOR ELAFIBRANOR ELAFIBRANOR STABILIZES NON-INVASIVE MARKERS OF LIVER FIBROSIS Source text: ID:nGNX41C5qs Further company coverage: IPN.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients